Recently, the FDA has authorized a new drug called bebtelovimab, a monoclonal therapy for COVID-19 patients. Patients as young as 12 that are high risk for sever illness can take this drug to prevent getting sicker or even end up in the hospital. Due to a shortage on drugs that have been proven effective in fighting the omicron variant, professionals have been faced with the difficult decision on who should receive the treatment. The latest authorization brings the total number of treatments for omicron to four.
To learn more, click here.